Acute hypoxia in tumors: implications for modifiers of radiation effects - PubMed (original) (raw)
Acute hypoxia in tumors: implications for modifiers of radiation effects
D J Chaplin et al. Int J Radiat Oncol Biol Phys. 1986 Aug.
Abstract
Radioresistant hypoxic cells have been shown to occur in nearly all the animal tumors studied to date. Furthermore, there is a large amount of evidence, albeit indirect, that hypoxic cells exist and impair the effectiveness of radiation therapy in some human cancers. Surprisingly little is known, however, about the natural history of such hypoxic cells. Recently in our laboratories, we have developed methods which enable us to select and analyse cells from tumors as a function of their distance from the tumor blood supply. Utilizing this technique, we have been able to demonstrate using SCCVII tumors greater than or equal to 500 mg that even cells close to the blood supply may become hypoxic at any particular time. This information provides direct evidence that, at least for that tumor, hypoxia can result from transient fluctuations in blood perfusion. The existence of acutely, as well as, chronically hypoxic cells within tumors has several implications for treatment strategies. Treatments designed to increase oxygen content in the blood may not be particularly effective in sensitizing acutely hypoxic cells. However small, freely diffusable radiosensitizers would distribute throughout the tumor, and should be equally effective in sensitizing both acutely and chronically hypoxic cells to radiation. Acute hypoxia may thus be the best possible indicator for the use of chemical radiosensitizers in radiation therapy.
Similar articles
- Nicotinamide, Fluosol DA and Carbogen: a strategy to reoxygenate acutely and chronically hypoxic cells in vivo.
Chaplin DJ, Horsman MR, Aoki DS. Chaplin DJ, et al. Br J Cancer. 1991 Jan;63(1):109-13. doi: 10.1038/bjc.1991.22. Br J Cancer. 1991. PMID: 1846549 Free PMC article. - Evaluation of the concept of "hypoxic fraction" as a descriptor of tumor oxygenation status.
Evans SM, Jenkins WT, Shapiro M, Koch CJ. Evans SM, et al. Adv Exp Med Biol. 1997;411:215-25. doi: 10.1007/978-1-4615-5865-1_26. Adv Exp Med Biol. 1997. PMID: 9269430 - The potential of using hyperthermia to eliminate radioresistant hypoxic cells.
Overgaard J, Grau C, Lindegaard JC, Horsman MR. Overgaard J, et al. Radiother Oncol. 1991;20 Suppl 1:113-6. doi: 10.1016/0167-8140(91)90197-o. Radiother Oncol. 1991. PMID: 2020761 - Tumor hypoxia: its impact on cancer therapy.
Moulder JE, Rockwell S. Moulder JE, et al. Cancer Metastasis Rev. 1987;5(4):313-41. doi: 10.1007/BF00055376. Cancer Metastasis Rev. 1987. PMID: 3552280 Review. - Chemical modifiers of cancer treatment.
Coleman CN, Bump EA, Kramer RA. Coleman CN, et al. J Clin Oncol. 1988 Apr;6(4):709-33. doi: 10.1200/JCO.1988.6.4.709. J Clin Oncol. 1988. PMID: 3282035 Review.
Cited by
- Hypoxia regulates SOX2 expression to promote prostate cancer cell invasion and sphere formation.
Bae KM, Dai Y, Vieweg J, Siemann DW. Bae KM, et al. Am J Cancer Res. 2016 May 1;6(5):1078-88. eCollection 2016. Am J Cancer Res. 2016. PMID: 27294000 Free PMC article. - Intra- and intertumor heterogeneities in total, chronic, and acute hypoxia in xenografted squamous cell carcinomas. Detection and quantification using (immuno-)fluorescence techniques.
Maftei CA, Bayer C, Shi K, Vaupel P. Maftei CA, et al. Strahlenther Onkol. 2012 Jul;188(7):606-15. doi: 10.1007/s00066-012-0105-4. Epub 2012 Jun 14. Strahlenther Onkol. 2012. PMID: 22695745 - Fluctuations in tumor blood flow under normotension and the effect of angiotensin II-induced hypertension.
Hori K, Suzuki M, Tanda S, Saito S, Shinozaki M, Zhang QH. Hori K, et al. Jpn J Cancer Res. 1991 Nov;82(11):1309-16. doi: 10.1111/j.1349-7006.1991.tb01797.x. Jpn J Cancer Res. 1991. PMID: 1752787 Free PMC article. - A phase II study of radiotherapy after hyperbaric oxygenation combined with interferon-beta and nimustine hydrochloride to treat supratentorial malignant gliomas.
Beppu T, Kamada K, Nakamura R, Oikawa H, Takeda M, Fukuda T, Arai H, Ogasawara K, Ogawa A. Beppu T, et al. J Neurooncol. 2003 Jan;61(2):161-70. doi: 10.1023/a:1022169107872. J Neurooncol. 2003. PMID: 12622455 Clinical Trial. - Chemosensitization by misonidazole in CCNU-treated spheroids and tumours.
Durand RE, Chaplin DJ. Durand RE, et al. Br J Cancer. 1987 Aug;56(2):103-9. doi: 10.1038/bjc.1987.165. Br J Cancer. 1987. PMID: 3663461 Free PMC article.